Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma.

Blood Cancer J · 2019 · PMC6386751 · PMID 30796199

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

HR-QoL responder analysis The proportion of patients reaching at least 5-point improvement in the GHS/QoL scale was higher in the Kd56 group up to week 48, although the difference between the groups did not reach statistical significance (Fig. 4a ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.